97 related articles for article (PubMed ID: 15899803)
21. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity.
Garcia-Hernandez Mde L; Gray A; Hubby B; Klinger OJ; Kast WM
Cancer Res; 2008 Feb; 68(3):861-9. PubMed ID: 18245488
[TBL] [Abstract][Full Text] [Related]
22. Versatile prostate cancer treatment with inducible caspase and interleukin-12.
Nikitina EY; Desai SA; Zhao X; Song W; Luo AZ; Gangula RD; Slawin KM; Spencer DM
Cancer Res; 2005 May; 65(10):4309-19. PubMed ID: 15899823
[TBL] [Abstract][Full Text] [Related]
23. Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model.
Isayeva T; Chanda D; Kallman L; Eltoum IE; Ponnazhagan S
Cancer Res; 2007 Jun; 67(12):5789-97. PubMed ID: 17575146
[TBL] [Abstract][Full Text] [Related]
24. Alpha-methylacyl-CoA racemase (P504S)/34betaE12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy.
Sung MT; Jiang Z; Montironi R; MacLennan GT; Mazzucchelli R; Cheng L
Hum Pathol; 2007 Feb; 38(2):332-41. PubMed ID: 17134736
[TBL] [Abstract][Full Text] [Related]
25. OSU-HDAC42, a histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model.
Sargeant AM; Rengel RC; Kulp SK; Klein RD; Clinton SK; Wang YC; Chen CS
Cancer Res; 2008 May; 68(10):3999-4009. PubMed ID: 18483287
[TBL] [Abstract][Full Text] [Related]
26. Interspecies comparison of prostate cancer gene-expression profiles reveals genes associated with aggressive tumors.
Kela I; Harmelin A; Waks T; Orr-Urtreger A; Domany E; Eshhar Z
Prostate; 2009 Jul; 69(10):1034-44. PubMed ID: 19343735
[TBL] [Abstract][Full Text] [Related]
27. Loss of Nkx3.1 expression in the transgenic adenocarcinoma of mouse prostate model.
Bethel CR; Bieberich CJ
Prostate; 2007 Dec; 67(16):1740-50. PubMed ID: 17929276
[TBL] [Abstract][Full Text] [Related]
28. Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death.
Rubin MA; Bismar TA; Andrén O; Mucci L; Kim R; Shen R; Ghosh D; Wei JT; Chinnaiyan AM; Adami HO; Kantoff PW; Johansson JE
Cancer Epidemiol Biomarkers Prev; 2005 Jun; 14(6):1424-32. PubMed ID: 15941951
[TBL] [Abstract][Full Text] [Related]
29. Conditional deletion of insulin-like growth factor-I receptor in prostate epithelium.
Sutherland BW; Knoblaugh SE; Kaplan-Lefko PJ; Wang F; Holzenberger M; Greenberg NM
Cancer Res; 2008 May; 68(9):3495-504. PubMed ID: 18451178
[TBL] [Abstract][Full Text] [Related]
30. Memory and cellular immunity induced by a DNA vaccine encoding self antigen TPD52 administered with soluble GM-CSF.
Lewis JD; Sullivan LA; Byrne JA; de Riese W; Bright RK
Cancer Immunol Immunother; 2009 Aug; 58(8):1337-49. PubMed ID: 19169682
[TBL] [Abstract][Full Text] [Related]
31. Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model.
Dzojic H; Loskog A; Tötterman TH; Essand M
Prostate; 2006 Jun; 66(8):831-8. PubMed ID: 16491482
[TBL] [Abstract][Full Text] [Related]
32. The resistance to the tumor suppressive effects of COX inhibitors and COX-2 gene disruption in TRAMP mice is associated with the loss of COX expression in prostate tissue.
Wang X; Colby JK; Yang P; Fischer SM; Newman RA; Klein RD
Carcinogenesis; 2008 Jan; 29(1):120-8. PubMed ID: 17942462
[TBL] [Abstract][Full Text] [Related]
33. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer.
Garcia-Hernandez Mde L; Gray A; Hubby B; Kast WM
Cancer Res; 2007 Feb; 67(3):1344-51. PubMed ID: 17283172
[TBL] [Abstract][Full Text] [Related]
34. Cancer immunomics: using autoantibody signatures in the early detection of prostate cancer.
Bradford TJ; Wang X; Chinnaiyan AM
Urol Oncol; 2006; 24(3):237-42. PubMed ID: 16678056
[TBL] [Abstract][Full Text] [Related]
35. Identification of autoantibodies elicited in a patient with prostate cancer presenting as dermatomyositis.
Mooney CJ; Dunphy EJ; Stone B; McNeel DG
Int J Urol; 2006 Mar; 13(3):211-7. PubMed ID: 16643611
[TBL] [Abstract][Full Text] [Related]
36. Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.
Morgenbesser SD; McLaren RP; Richards B; Zhang M; Akmaev VR; Winter SF; Mineva ND; Kaplan-Lefko PJ; Foster BA; Cook BP; Dufault MR; Cao X; Wang CJ; Teicher BA; Klinger KW; Greenberg NM; Madden SL
Prostate; 2007 Jan; 67(1):83-106. PubMed ID: 17013881
[TBL] [Abstract][Full Text] [Related]
37. The aryl hydrocarbon receptor inhibits prostate carcinogenesis in TRAMP mice.
Fritz WA; Lin TM; Cardiff RD; Peterson RE
Carcinogenesis; 2007 Feb; 28(2):497-505. PubMed ID: 17052998
[TBL] [Abstract][Full Text] [Related]
38. HIP1: trafficking roles and regulation of tumorigenesis.
Hyun TS; Ross TS
Trends Mol Med; 2004 Apr; 10(4):194-9. PubMed ID: 15059611
[TBL] [Abstract][Full Text] [Related]
39. Increased urokinase-type plasminogen activator receptor and epidermal growth factor receptor in serum of patients with prostate cancer.
Milanese G; Dellabella M; Fazioli F; Pierpaoli E; Polito M; Siednius N; Montironi R; Blasi F; Muzzonigro G
J Urol; 2009 Mar; 181(3):1393-400. PubMed ID: 19157433
[TBL] [Abstract][Full Text] [Related]
40. Adenocarcina of the mouse prostate growth inhibition by celecoxib: downregulation of transcription factors involved in COX-2 inhibition.
Narayanan BA; Narayanan NK; Pttman B; Reddy BS
Prostate; 2006 Feb; 66(3):257-65. PubMed ID: 16175586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
